SOURCE-LINKED STUDY SUMMARY
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Abstract summarizedQuality not appraised
- What was studied
- Randomized, open-label phase 2 trial testing whether tesamorelin improves cognition in people with HIV and abdominal obesity.
- Who / model studied
- Seventy-three virally suppressed participants with HIV and abdominal obesity, allocated 3:2.
- Studied dose & schedule
- Tesamorelin 2 mg subcutaneously daily versus standard care for 6 months.
- What the study found
- Cognitive improvement did not differ between groups (P=.673). Waist circumference fell more with tesamorelin (median difference −2.7 cm; P=.015). Higher IGF-1 did not correlate with cognitive change or waist change.
- Limitations & context
- Abstract assessment; insufficient power, open-label design and no placebo arm limit inference. Adverse-event results are not reported in the abstract.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1093/infdis/jiaf012